Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TK001
- Development stage
- Unknown
- Lead developer
- Jiangsu T-Mab Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Ophthalmic
01
Overview
TK001 is a full-length recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), developed by Jiangsu T-Mab Biopharma Co., Ltd. for the treatment of neovascular age-related macular degeneration (nAMD). By binding to VEGF, TK001 inhibits the signaling pathways responsible for abnormal blood vessel growth and vascular leakage in the retina, which are the primary drivers of vision loss in nAMD. The drug is administered via intravitreal injection and has been evaluated in Phase I clinical trials to assess its safety, pharmacokinetics, immunogenicity, and preliminary efficacy in patients receiving both single and multiple doses.
- Other names
- humanized IgG1 anti-ErbB3 monoclonal antibodyTakis ErbB3 monoclonal antibody
02
Targets
VEGF-A165 (Vascular endothelial growth factor A isoform 165)
Beyond the preview
Go deeper on TK001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TK001.